DAB389IL-2 data

SRGN said its preliminary analysis of a Phase II double-blind, placebo-controlled trial of its IL-2 fusion protein for moderate-to-severe psoriasis indicates that evaluable patients who completed the full course of treatment had a mean improvement of about 40 percent from baseline after four weeks of treatment.

Based on the results, the company plans to design another Phase II trial to refine dose and schedule of administration, and has been notified by the FDA that it may proceed with the new trial. The psoriasis program had been put on clinical hold in January following the report of a blood clot in one patient. The company halted the trial to examine all data at that time, and forwarded the information to the FDA. ...